Skip to main content
. 2017 Dec 21;9(7):7672–7683. doi: 10.18632/oncotarget.23584

Figure 8. Pooled estimates of grade 3 or 4 treatment-related adverse events rates for anti-PD-1/PD-L1 antibodies and docetaxel.

Figure 8